Sugi Predict

Sugi Predict / Compounds / SCHEMBL5452364

SCHEMBL5452364

SCHEMBL5452364

Nc1ccc(S(=O)(=O)NC2CCC2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.75
▸ KDM4E B2RXH2 1/20 0.75
▸ RECQL P46063 1/20 0.75
▸ ALDH1A1 P00352 8/20 0.62
▸ CYP3A4 P08684 1/20 0.62
▸ TSHR P16473 1/20 0.62
▸ MAPK1 P28482 1/20 0.62
▸ HTT P42858 1/20 0.62
▸ LMNA P02545 3/20 0.57
▸ HPGD P15428 1/20 0.57
▸ MEN1 O00255 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ GAA P10253 2/20 0.53
▸ PDE4A P27815 1/20 0.50
▸ PDE4B Q07343 1/20 0.50
▸ PDE4C Q08493 1/20 0.50
▸ PDE4D Q08499 1/20 0.50
▸ CA1 P00915 1/20 0.50
▸ CA2 P00918 1/20 0.50
▸ MMP1 P03956 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4066993 0.96 SMN1; SMN2 (0.81) SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4
SCHEMBL13845977 0.95 SMN1; SMN2 (0.79) SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4
SCHEMBL4068438 0.95 SMN1; SMN2 (0.79) SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4
SCHEMBL16093290 0.95 SMN1; SMN2 (0.79) SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4
SCHEMBL4071039 0.92 SMN1; SMN2 (0.68) SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4
SCHEMBL12418058 0.90 SMN1; SMN2 (0.71) SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4
SCHEMBL11253764 0.86 SMN1; SMN2 (0.65) SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4
SCHEMBL23093579 0.84 KDM4E (0.58) SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4
SCHEMBL6191704 0.84 SMN1; SMN2 (0.58) SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4
SCHEMBL24477877 0.84 SMN1; SMN2 (0.58) SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024243485-A1 CDK2 INHIBITORS AND USES THEREOF ODYSSEY THERAPEUTICS, INC. (US) 2024-11-28 — — WO disclosed
WO-2020183011-A1 HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER INSTITUT CURIE (FR) 2020-09-17 — — WO disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
EP-3696174-A1 HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals Incorporated (US) 2020-08-19 — — EP disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 — — US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 — — US disclosed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 — — US disclosed
EP-3208272-A1 HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals Incorporated (US) 2017-08-23 — — EP disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 — — US disclosed
US-9499535-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2016-11-22 — — US disclosed
WO-2012101068-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-08-02 — — WO disclosed
US-20120190677-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — US disclosed
US-20070010526-A1 Therapeutic isoquinoline compounds ASTRAZENECA AB (SE) 2007-01-11 — — US disclosed
EP-1406876-B1 2-ANILINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS ASTRAZENECA AB (SE) 2006-12-27 — — EP disclosed
US-6939872-B2 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors ASTRAZENECA AB (SE) 2005-09-06 — — US disclosed
US-20040198757-A1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors ASTRAZENECA AB (SE) 2004-10-07 — — US disclosed
EP-1451172-A1 THERAPEUTIC ISOQUINOLINE COMPOUNDS AstraZeneca AB (SE) 2004-09-01 — — EP disclosed
EP-1406876-A1 2-ANILINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS Astrazeneca AB (SE) 2004-04-14 — — EP disclosed
WO-2003037887-A1 THERAPEUTIC ISOQUINOLINE COMPOUNDS ASTRAZENECA AB (SE) 2003-05-08 — — WO disclosed
WO-2002096887-A1 2-ANILINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS ASTRAZENECA AB (SE) 2002-12-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010526-A1 Therapeutic isoquinoline compounds HTR1B, HTR1D, HTR1A SMN1; SMN2 773/4885KDM4E 1824/4885RECQL 197/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK SMN1; SMN2 882/4885KDM4E 1662/4885RECQL 2017/4885
US-20040198757-A1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors CCNT1, CCNI, CDK2 SMN1; SMN2 3374/4885KDM4E 1122/4885RECQL 96/4885
US-20120190677-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES RAB1A, RABL3, RAB7A SMN1; SMN2 1218/4885KDM4E 1324/4885RECQL 17/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK SMN1; SMN2 986/4885KDM4E 1645/4885RECQL 2141/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK SMN1; SMN2 986/4885KDM4E 1645/4885RECQL 2141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.